单倍体BMT联合移植后环磷酰胺强化GVHD预防治疗重型再生障碍性贫血
37例重型再生障碍性贫血(SAA)患者接受减低强度预处理后单倍体骨髓移植,并采用含移植后环磷酰胺的强化GVHD预防。中位随访32个月,全部患者1年和2年总生存率均为94%,II-IV级急性GVHD第100天累积发生率为11%,2年慢性GVHD累积指数为8%。复发/难治组20例均存活且无病无活动性GVHD,初治组移植失败率较高但400 cGy全身照射后植入持久。
要点
- 单倍体BMT联合移植后环磷酰胺可使复发/难治SAA患者获得高生存且无活动性GVHD。
- 初治SAA患者移植失败率较高,但400 cGy全身照射可改善植入且不增加早期毒性。
- 该方案为初治SAA提供快速、安全、治愈性移植的可能范式转变。
核心结论
- 含移植后环磷酰胺的单倍体BMT是SAA的潜在治愈手段,复发/难治患者全部存活且无病无活动性GVHD。
- 初治SAA患者移植失败率较高,但将全身照射剂量增至400 cGy可获得持久植入且不增加早期毒性。
研究设计与样本
- 研究纳入37例SAA患者,包括20例复发/难治(R/R)和17例初治(TN)患者,接受相关HLA单倍体供者移植。
- 预处理为减低强度方案,GVHD预防包含移植后环磷酰胺;中位随访32个月(90%CI,29-44),中位年龄25岁(范围4-69)。
主要发现
- 37例中4例(11%)发生移植失败,其中R/R组20例中1例原发失败,TN组17例中3例失败(1例原发,2例继发)。
- 接受400 cGy全身照射的10例患者均未发生移植失败。
- 2例移植失败患者死于感染,2例经第二次单倍体BMT挽救。
- 全部患者1年和2年总生存率均为94%(90%CI,88-100)。
- 第100天II-IV级急性GVHD累积发生率为11%,2年慢性GVHD累积指数为8%。
关键数值与推荐
- 中性粒细胞恢复中位时间为17天(范围15-88)。
- 接受相同非清髓方案联合移植后环磷酰胺但配型相合供者移植的10例SAA患者结果相似。
- R/R组20例患者目前均存活、无病且无活动性GVHD证据。
临床怎么用
- 单倍体BMT联合移植后环磷酰胺可作为SAA的潜在治愈选择,尤其适用于复发/难治患者。
- 对初治SAA患者采用该方案时,可考虑将全身照射剂量增至400 cGy以降低移植失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe aplastic anemia (SAA) is a stem cell disorder often treated with bone marrow transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA-haploidentical (haplo) donors after reduced-intensity conditioning with intensive graft-versus-host disease (GVHD) prophylaxis including posttransplantation cyclophosphamide are presented here from 37 SAA, 20 relapsed/refractory (R/R), and 17 treatment-naïve (TN) SAA patients. Median follow-up is 32 months (90% confidence interval [CI], 29-44). The median age was 25 (range, 4-69) years. The median time to neutrophil recovery was 17 days (range, 15-88). Four of 37 patients (11%) experienced graft failure (GF). There was 1 primary GF of 20 patients in the R/R group and 3 of 17 in the TN group at 200 cGy (1 primary, 2 secondary), but none in the 10 patients who received 400 cGy total body irradiation. Two patients with GF succumbed to infection and 2 were rescued with second haplo BMT. The overall survival for all patients is 94% (90% CI, 88-100) at 1 and 2 years. The cumulative incidence of grade II-IV acute GVHD at day 100 is 11%. The cumulative index of chronic GVHD at 2 years is 8%. Similar results were seen in 10 SAA patients who received the identical nonmyeloablative regimen with posttransplant cyclophosphamide but matched donor transplants. Haplo BMT with posttransplant cyclophosphamide represents a potential cure in SAA, with all 20 R/R currently alive, disease-free, and with no evidence of active GVHD. Extending this approach to TN patients was associated with higher GF rates, but an increase in total body irradiation dose to 400 cGy was associated with durable engraftment without greater early toxicity. Nonmyeloablative haplo BMT in TN SAA could lead to a paradigm shift, such that essentially all patients can proceed quickly to safe, curative BMT. These trials were registered at www.cincialtrials.gov as #NCT02224872) and #NCT02833805.
引用
- DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020. PMID: 32343796. doi:10.1182/bloodadvances.2020001729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。